LabCorp's Covance Licenses Genfit's NASH Test

Jan 03, 2019

NEW YORK (360Dx) – Laboratory Corporation of America announced today that its Covance drug development business has signed a licensing agreement with Genfit to use a non-alcoholic steatohepatitis liver diagnostic (NASH) assay in the clinical research market.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

The Ultimate Guide to Mouse Clinical Trials

A Guide to Selecting Your Next Immuno-Oncology Model

Feb

14

Featured Webinar

Transcriptome of an Agricultural Pest Delineated by Oxford Nanopore RNA-Seq

This webinar will describe a project that applied Oxford Nanopore long-read RNA-seq to explore the transcriptional landscape of a damaging agricultural pest.

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Main menu